Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

Albertsons Companies , Inc. (NYSE:ACI) stands as a prominent player in the U.S. grocery market, with annual revenue reaching $79.93 billion, leveraging its scale and diverse offerings to maintain a ...

Visa Inc . (NYSE:V), a global leader in digital payments, continues to demonstrate strong performance and resilience in the ...

Is Bitcoin Bottom In? BTC's Price Action is Inverse of December Peak Above $108K BTC's latest price action seems to contrast sharply with the uptrend exhaustion observed at record highs above $ ...

"As published in The Lancet, in a prespecified analysis in the subset of patients proven to have PD-L1 expression of at least 50%, Libtayo reduced the risk of death by 43% compared to chemotherapy.

Libtayo was approved in 2018 for advanced cutaneous squamous cell carcinoma, and since then has also been cleared for basal cell carcinoma and most recently first-line non-small cell lung cancer ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

“At the first prespecified interim analysis, Libtayo achieved a remarkably high bar in improving disease-free survival in high-risk cutaneous squamous cell carcinoma. With no currently approved ...

Additionally, the success of Libtayo in the treatment of cutaneous squamous cell carcinoma further supports the optimistic outlook. These factors collectively contribute to the positive assessment ...

Regeneron Pharmaceuticals has shared positive results from a late-stage trial of Libtayo (cemiplimab) in patients with high-risk cutaneous squamous cell carcinoma (CSCC) after surgery. The phase 3 ...

EYLEA HD achieved $6 billion in 2024 sales, with FDA decisions on extended dosing and pre-filled syringes due in 2025. Dupixent sales topped $15 billion in 2024, with strong COPD launch and Phase ...